| 宿 濛,张 睿,王 哲.西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移的近期疗效观察[J].肿瘤学杂志,2015,21(6):491-495. |
| 西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移的近期疗效观察 |
| Short-term Response of Cetuximab Combined with FOLFIRI Regimen Chemotherapy in the Treatment for Colorectal Cancer Patients with Liver Metastases |
| 投稿时间：2015-01-09 |
| DOI：10.11735/j.issn.1671-170X.2015.06.B010 |
|
 |
| 中文关键词: 肠肿瘤 西妥昔单抗 药物疗法 不良反应 肿瘤转移 肝肿瘤 |
| 英文关键词:colorectal neoplasms cetuximab drug therapy toxicity neoplasm metastasis liver neoplasms |
| 基金项目: |
|
| 摘要点击次数: 2496 |
| 全文下载次数: 719 |
| 中文摘要: |
| 摘 要：［目的］ 评价西妥昔单抗联合化疗治疗大肠癌肝转移的近期疗效和不良反应。［方法］ 35例大肠癌肝转移患者采用西妥昔单抗、伊立替康、亚叶酸钙、氟尿嘧啶联合化疗，2周重复1次。4周期化疗后评价疗效及不良反应。［结果］ 全组35例均可评价疗效，完全缓解（CR）2例，部分缓解（PR）9例，疾病稳定（SD）18例，疾病进展（PD）6例，有效率（RR）为31.43%，疾病控制率（DCR）为82.86%；中位无进展生存时间（PFS）为15.2个月，中位总生存时间（OS）为50.9个月。不良反应主要表现为痤疮样皮疹、腹泻和血液学毒性。［结论］ 西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移疗效肯定，其不良反应可以耐受。 |
| 英文摘要: |
| Abstract：［Purpose］To evaluate the short-term response and toxicity of cetuximab combined with chemotherapy in the treatment for colorectal cancer patients with liver metastases. ［Methods］ Thirty-five colorectal cancer patients with liver metastases were treated with cetuximab，irinotecan，leucovorin and 5-Fu，every 2 weeks as a cycle. Short-term response and toxicity were evaluated after 4 cycles of chemotherapy.［Results］ Efficacy could be evaluated in all the 35 patients. Of them，2 patients were complete response(CR）；9 patients，partial response(PR)；18 patients，stable disease(SD) and 6 patients，progression disease(PD). The response rate(RR) was 31.43% and the disease control rate(DCR) was 82.86%. Progression-free survival(PFS) was 15.2 months and overall survival(OS) was 50.9 months. The common toxicities were acne-like rash，diarrhea and hematology toxicities. ［Conclusion］ Cetuximab combined with FOLFIRI regimen chemotherapy have certain efficacy in the treatment for colorectal cancer with liver metastases，and the toxicities are tolerable. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |